Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database

被引:9
|
作者
Noda, Aoi [1 ,2 ,3 ]
Sakai, Takamasa [4 ]
Obara, Taku [1 ,2 ,3 ]
Miyazaki, Makoto [5 ]
Tsuchiya, Masami [5 ,6 ]
Oyanagi, Gen [3 ]
Murai, Yuriko [7 ]
Mano, Nariyasu [3 ,5 ]
机构
[1] Tohoku Univ, Div Prevent Med & Epidemiol, Tohoku Med Megabank Org, Sendai, Miyagi, Japan
[2] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan
[3] Tohoku Univ Hosp, Dept Pharmaceut Sci, Sendai, Miyagi, Japan
[4] Meijo Univ, Fac Pharm, Drug Informat, Nagoya, Aichi, Japan
[5] Tohoku Univ, Lab Clin Pharm, Grad Sch Pharmaceut Sci, Sendai, Miyagi, Japan
[6] Miyagi Canc Ctr, Dept Pharm, Natori, Miyagi, Japan
[7] Tohoku Med & Pharmaceut Univ, Dept Clin Pharmaceut, Sendai, Miyagi, Japan
来源
BMC PHARMACOLOGY & TOXICOLOGY | 2020年 / 21卷 / 01期
基金
日本学术振兴会;
关键词
Adverse drug reaction; Pediatric patients; Children; The JADER; Spontaneous reports; Drug safety; Pharmacovigilance; Signal detection; STEVENS-JOHNSON SYNDROME; CHILDREN; RISK;
D O I
10.1186/s40360-020-00412-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background There are no reports on investigations of the characteristics of adverse drug reaction (ADR) reports for pediatric patients in the Japanese Adverse Drug Event Report database (JADER) and the utility of database for drug safety surveillance in these patients. Method We aimed to evaluate ADR reports for pediatric patients in the JADER. We used spontaneous ADR reports included in the JADER since April 1, 2004, to December 31, 2017, which was downloaded in April 2018. In a total of 504,407 ADR reports, the number of spontaneous reports was 386,400 (76.6%), in which 37,534 (7.4%) were unknown age reports. After extraction of 27,800 ADR reports for children aged < 10 and 10-19 years, we excepted for ADR reports associated with a vaccine (n = 6355) and no-suspected drug reports (n = 86). A total of 21,359 (4.2%) reports were finally included in this analysis. Results More than half of the ADR reports were for children aged < 10 years. Approximately 30% of ADR reports had multiple suspected drugs, which did not differ by age. The percentages of fatal outcomes of ADRs among patients aged < 10 and 10-19 years were 4.7 and 3.9%, respectively. The most frequently reported drug, reaction, and drug-reaction pair were oseltamivir, abnormal behavior, and oseltamivir and abnormal behavior, respectively. Conclusion We clarified the characteristics of ADR reports for Japanese children by using the JADER. ADR report databases, especially those for pediatric patients, are valuable pharmacovigilance tools in Japan and other countries. Therefore, a proper understanding of the characteristics of the ADR reports in the JADER is important. Additionally, potential signals for ADRs in pediatric patients should be monitored continuously and carefully.
引用
下载
收藏
页数:10
相关论文
共 50 条
  • [21] Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy
    Akio Negishi
    Shinji Oshima
    Norimitsu Horii
    Mizue Mutoh
    Naoko Inoue
    Sachihiko Numajiri
    Shigeru Ohshima
    Daisuke Kobayashi
    Drugs - Real World Outcomes, 2021, 8 : 49 - 61
  • [22] Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy
    Negishi, Akio
    Oshima, Shinji
    Horii, Norimitsu
    Mutoh, Mizue
    Inoue, Naoko
    Numajiri, Sachihiko
    Ohshima, Shigeru
    Kobayashi, Daisuke
    DRUGS-REAL WORLD OUTCOMES, 2021, 8 (01) : 49 - 61
  • [23] SPONTANEOUS ADVERSE DRUG EVENT REPORTS TO THE ADVERSE DRUG EVENT MANAGER (ADEM)
    Lund, M.
    Vinther, S.
    Klarskov, P.
    Harboe, K. M.
    Jimenez-Solem, E.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E127 - E128
  • [24] Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database
    Nagai, Junko
    Ishikawa, Yoichi
    PLOS ONE, 2021, 16 (12):
  • [25] Adverse Drug Events Caused by Drugs Contraindicated for Coadministration Reported in the Japanese Adverse Drug Event Report Database and Recognized by Reporters
    Negishi, Akio
    Oshima, Shinji
    Horii, Norimitsu
    Mutoh, Mizue
    Inoue, Naoko
    Numajiri, Sachihiko
    Ohshima, Shigeru
    Kobayashi, Daisuke
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2021, 44 (07) : 932 - 936
  • [26] Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database
    Yomei Matsuoka
    Mamoru Narukawa
    Therapeutic Innovation & Regulatory Science, 2018, 52 : 339 - 347
  • [27] Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database
    Matsuoka, Yomei
    Narukawa, Mamoru
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (03) : 339 - 347
  • [28] Evaluation of Drug-Induced Photosensitivity Using the Japanese Adverse Drug Event Report (JADER) Database
    Nakao, Satoshi
    Hatahira, Haruna
    Sasaoka, Sayaka
    Hasegawa, Shiori
    Motooka, Yumi
    Ueda, Natsumi
    Abe, Junko
    Fukuda, Akiho
    Naganuma, Misa
    Kanoh, Hiroyuki
    Seishima, Mariko
    Ishiguro, Motoyuki
    Kinosada, Yasutomi
    Nakamura, Mitsuhiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2017, 40 (12) : 2158 - 2165
  • [29] Risk of delirium with antiepileptic drug use: a study based on the Japanese Adverse Drug Event Report database
    Kubo, Toshiki
    Sogawa, Rintaro
    Tsuruhashi, Satoko
    Murakawa-Hirachi, Toru
    Matsuoka, Ayaka
    Mizoguchi, Yoshito
    Monji, Akira
    Shimanoe, Chisato
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (05) : 1260 - 1266
  • [30] Risk of delirium with antiepileptic drug use: a study based on the Japanese Adverse Drug Event Report database
    Toshiki Kubo
    Rintaro Sogawa
    Satoko Tsuruhashi
    Toru Murakawa-Hirachi
    Ayaka Matsuoka
    Yoshito Mizoguchi
    Akira Monji
    Chisato Shimanoe
    International Journal of Clinical Pharmacy, 2023, 45 : 1260 - 1266